v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

Note 11. Segment Information

 

The Company operates as a single operating segment focused on the development of novel small-molecule therapeutics targeting biological pathways implicated in cancer, including its lead investigational candidate, Telomir-Zn. The CODM for the Company is the Chief Executive Officer (the “CEO”). The Company’s CEO reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance and allocating resources. Accordingly, the Company has determined that it has a single reportable and operating segment structure.

 

 

Telomir Pharmaceuticals, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026

(unaudited)

 

The CEO uses aggregate net loss to allocate resources in the annual budgeting and forecasting process and also uses that measure as a basis for evaluating financial performance regularly by comparing actual results with established budgets and forecasts.

 

The accounting policies of the Company’s single segment are the same as those described in the summary of significant accounting policies within Note 2. The CEO assesses performance for the Company and decides how to allocate resources based on the aggregate net loss that is also reported on the income statement as net loss. The measure of segment assets is reported on the balance sheets as total assets.

 

The table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

 

   2026   2025   2026   2025 
  

For the three months ended

June 30,

  

For the six months ended

June 30,

 
   2026   2025   2026   2025 
Revenues  $—   $—   $—   $— 
                     
Operating costs:                    
General and administrative expenses   1,320,002    5,027,071    1,893,541    6,877,857 
Research and development expenses   444,674    42,839    912,471    379,835 
Total operating costs   1,764,676    5,069,910    2,806,012    7,257,692 
                     
Other income (expense):                    
Interest income   46,176    1,362    97,820    9,362 
Interest expense   (3,028)   (1,342)   (4,283)   (1,388)
Total other income, net   43,148    20    93,537    7,974 
Segment net loss  $(1,721,528)  $(5,069,890)  $(2,712,475)  $(7,249,718)